Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07022223 | Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma | recruiting | Phase 2 | 51 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05253495 | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma(RADICAL) | recruiting | Phase 2 | 80 | New York Medical CollegeOTHER | 1 | Jun 13, 2025 |
| clinicaltrials |
| NCT07014943 | High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 34 | Sichuan UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07012447 | Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations | recruiting | Phase 2 | 32 | yuejun LiuOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06793410 | Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation | recruiting | Phase 2 | 100 | Vastra Gotaland RegionOTHER_GOV | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | recruiting | Phase 1 / Phase 2 | 128 | Indapta Therapeutics, INC.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06846489 | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma | recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07000617 | A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma | recruiting | Phase 2 | 57 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03937544 | Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL | recruiting | Phase 2 / Phase 3 | 10 | National University of MalaysiaOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06014073 | TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06323525 | TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06935162 | Teclistamab in Previously Treated AL Amyloidosis | recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06244368 | GVM±R in Patients With Relapsed or Refractory Aggressive NHL. | recruiting | Phase 2 | 115 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06971380 | Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis | recruiting | Phase 2 | 180 | Polina StepenskyOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05294055 | Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma | recruiting | Phase 2 | 120 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06925464 | CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas | recruiting | Phase 1 / Phase 2 | 36 | Beijing GoBroad HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06686108 | Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention | recruiting | Phase 2 | 59 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06959732 | Zanubrutinib Combined With G-CVP in Previously Untreated FL | recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT03509961 | The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | recruiting | Phase 2 | 95 | Pediatric Transplantation & Cellular Therapy ConsortiumOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) | recruiting | Phase 1 / Phase 2 | 37 | IDP Discovery Pharma S.L.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05863234 | Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia | recruiting | Phase 1 / Phase 2 | 7 | Hiroshima University HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT03571568 | A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL | recruiting | Phase 1 / Phase 2 | 140 | BioInvent International ABINDUSTRY | 6 | Apr 24, 2025 | clinicaltrials |
| NCT04737889 | Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 23, 2025 | clinicaltrials |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | recruiting | Phase 1 / Phase 2 | 123 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05635162 | Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma(ZEBRA) | recruiting | Phase 2 | 50 | University College, LondonOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06140966 | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | recruiting | Phase 2 | 54 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT03936153 | Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 2 | 170 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT06918912 | Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure(LORELY) | recruiting | Phase 2 | 50 | Istituto Clinico HumanitasOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06911710 | The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors(CAR-T) | recruiting | Phase 1 / Phase 2 | 90 | Tianjin Medical University General HospitalOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06760039 | Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL | recruiting | Phase 1 / Phase 2 | 112 | Sun Yat-sen UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06484829 | Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 144 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06891157 | Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes | recruiting | Phase 2 | 148 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT04513639 | The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study | recruiting | Phase 2 / Phase 3 | 176 | Oslo University HospitalOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06758375 | Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients | recruiting | Phase 2 | 10 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06764017 | CHiR Therapy for Elderly DLBCL Intolerant to Chemo | recruiting | Phase 2 | 30 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 19, 2025 | clinicaltrials |
| NCT06758037 | Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy(HiR+X) | recruiting | Phase 2 | 50 | First Affiliated Hospital of Ningbo UniversityNETWORK | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06879379 | KPD Consolidation After ASCT in NDMM Patients | recruiting | Phase 2 / Phase 3 | 202 | Peking University People's HospitalOTHER | 1 | Mar 17, 2025 | clinicaltrials |
| NCT05595447 | Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 / Phase 3 | 20 | Hospital Regional de Alta Especialidad del BajioOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT06848569 | Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II Study | recruiting | Phase 2 | 73 | Sun Yat-sen UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04271644 | BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04776330 | a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease | recruiting | Phase 1 / Phase 2 | 80 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06743945 | POLA-R-CHP in the First-line Treatment of Transformed DLBCL | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06151080 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | recruiting | Phase 2 | 38 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06151106 | Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158386 | Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158412 | All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma | recruiting | Phase 2 | 25 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06824883 | Sintilimab, Pegaspargase Plus GemOx for Untreated Extranodal NK/T-Cell Lymphoma | recruiting | Phase 2 | 49 | Peking Union Medical College HospitalOTHER | 1 | Feb 13, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 15, 2025source: clinicaltrials